Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA List Of Potential Safety Signals Has 3 Pfizer Drugs, Echoes Drug Watch Site

Executive Summary

FDA's quarterly report that lists potential signals of serious risks for drugs is similar in design to a program that the agency proposed and then withdrew following industry criticism

You may also be interested in...



CBER's Quarterly Safety Review Procedures Less Centralized Than CDER's

Under FDAAA, both centers are required to publish evaluations of AERS data. CBER’s review effort is more specialized, while CDER’s procedures are more centralized.

Additional Risks Of I.V. Anticonvulsants To Be Taken Up By FDA Panel

A joint advisory committee will determine if regulatory action is necessary to reduce risks from intravenous administration of phenytoin and fosphenytoin, including the risk of a skin disease that can lead to amputation.

Drug Safety Should Focus On “Maximizing Benefit,” Not Just “Minimizing Risk” – FDA’s Goodman

Agency’s acting chief scientist emphasizes need for communication “in the face of uncertainty” and rejects the “either/or” choice of personalized medicine versus comparative effectiveness.

Related Content

UsernamePublicRestriction

Register

PS050067

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel